Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
1.320
+0.040 (3.13%)
At close: Aug 22, 2025, 4:00 PM
1.340
+0.020 (1.52%)
After-hours: Aug 22, 2025, 7:14 PM EDT
Werewolf Therapeutics Employees
Werewolf Therapeutics had 46 employees as of December 31, 2024. The number of employees decreased by 1 or -2.13% compared to the previous year.
Employees
46
Change (1Y)
-1
Growth (1Y)
-2.13%
Revenue / Employee
n/a
Profits / Employee
-$1,590,087
Market Cap
60.36M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 46 | -1 | -2.13% |
Dec 31, 2023 | 47 | 1 | 2.17% |
Dec 31, 2022 | 46 | 7 | 17.95% |
Dec 31, 2021 | 39 | 15 | 62.50% |
Dec 31, 2020 | 24 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
HOWL News
- 10 days ago - Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics to Participate in the BIO International Convention - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting - GlobeNewsWire